Cargando…
Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis
This systematic review aimed to compare extended infusion or continuous infusion with bolus infusion for febrile neutropenia (FN). We included clinical trials comparing extended or continuous infusion with bolus infusion of beta-lactam antibiotics as empirical treatment for FN and evaluated the clin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295281/ https://www.ncbi.nlm.nih.gov/pubmed/37370343 http://dx.doi.org/10.3390/antibiotics12061024 |
_version_ | 1785063383157964800 |
---|---|
author | Ishikawa, Kazuhiro Shibutani, Koko Kawai, Fujimi Ota, Erika Takahashi, Osamu Mori, Nobuyoshi |
author_facet | Ishikawa, Kazuhiro Shibutani, Koko Kawai, Fujimi Ota, Erika Takahashi, Osamu Mori, Nobuyoshi |
author_sort | Ishikawa, Kazuhiro |
collection | PubMed |
description | This systematic review aimed to compare extended infusion or continuous infusion with bolus infusion for febrile neutropenia (FN). We included clinical trials comparing extended or continuous infusion with bolus infusion of beta-lactam antibiotics as empirical treatment for FN and evaluated the clinical failure, all-cause mortality, and adverse event rates. Five articles (three randomized controlled trials (RCTs) and two retrospective studies) from 2014 to 2022 were included. Clinical failure was assessed with a risk ratio (RR) (95% coincident interval (CI)) of 0.74 (0.53, 1.05) and odds ratio (OR) (95% CI) of 0.14 (0.02, 1.17) in the 2 RCTs and retrospective studies, respectively. All-cause mortality was assessed with an RR (95% CI) of 1.25 (0.44, 3.54) and OR (95% CI) of 1.00 (0.44, 2.23) in the RCTs and retrospective studies, respectively. Only 1 RCT evaluated adverse events (with an RR (95% CI) of 0.46 (0.13, 1.65)). The quality of evidence was “low” for clinical failure and all-cause mortality in the RCTs. In the retrospective studies, the clinical failure and all-cause mortality evidence qualities were considered “very low” due to the study design. Extended or continuous infusion of beta-lactam antibiotics did not reduce mortality better than bolus infusion but was associated with shorter fever durations and fewer adverse events. |
format | Online Article Text |
id | pubmed-10295281 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102952812023-06-28 Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis Ishikawa, Kazuhiro Shibutani, Koko Kawai, Fujimi Ota, Erika Takahashi, Osamu Mori, Nobuyoshi Antibiotics (Basel) Review This systematic review aimed to compare extended infusion or continuous infusion with bolus infusion for febrile neutropenia (FN). We included clinical trials comparing extended or continuous infusion with bolus infusion of beta-lactam antibiotics as empirical treatment for FN and evaluated the clinical failure, all-cause mortality, and adverse event rates. Five articles (three randomized controlled trials (RCTs) and two retrospective studies) from 2014 to 2022 were included. Clinical failure was assessed with a risk ratio (RR) (95% coincident interval (CI)) of 0.74 (0.53, 1.05) and odds ratio (OR) (95% CI) of 0.14 (0.02, 1.17) in the 2 RCTs and retrospective studies, respectively. All-cause mortality was assessed with an RR (95% CI) of 1.25 (0.44, 3.54) and OR (95% CI) of 1.00 (0.44, 2.23) in the RCTs and retrospective studies, respectively. Only 1 RCT evaluated adverse events (with an RR (95% CI) of 0.46 (0.13, 1.65)). The quality of evidence was “low” for clinical failure and all-cause mortality in the RCTs. In the retrospective studies, the clinical failure and all-cause mortality evidence qualities were considered “very low” due to the study design. Extended or continuous infusion of beta-lactam antibiotics did not reduce mortality better than bolus infusion but was associated with shorter fever durations and fewer adverse events. MDPI 2023-06-07 /pmc/articles/PMC10295281/ /pubmed/37370343 http://dx.doi.org/10.3390/antibiotics12061024 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ishikawa, Kazuhiro Shibutani, Koko Kawai, Fujimi Ota, Erika Takahashi, Osamu Mori, Nobuyoshi Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title | Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title_full | Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title_fullStr | Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title_short | Effectiveness of Extended or Continuous vs. Bolus Infusion of Broad-Spectrum Beta-Lactam Antibiotics for Febrile Neutropenia: A Systematic Review and Meta-Analysis |
title_sort | effectiveness of extended or continuous vs. bolus infusion of broad-spectrum beta-lactam antibiotics for febrile neutropenia: a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295281/ https://www.ncbi.nlm.nih.gov/pubmed/37370343 http://dx.doi.org/10.3390/antibiotics12061024 |
work_keys_str_mv | AT ishikawakazuhiro effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis AT shibutanikoko effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis AT kawaifujimi effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis AT otaerika effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis AT takahashiosamu effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis AT morinobuyoshi effectivenessofextendedorcontinuousvsbolusinfusionofbroadspectrumbetalactamantibioticsforfebrileneutropeniaasystematicreviewandmetaanalysis |